Loading stock data…
CareDx (CDNA)
$29.28+0.46 (+1.60%)
Market ClosedLast close Jun 29
CareDx, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
CareDx, Inc. in the Healthcare sector is trading at $29.28 with a market capitalization of $1.3B. Wall Street consensus targets $25.80 (5 analysts), implying a -11.9% move over the next 12 months. The stock is currently near its 52-week high of $29.58, remaining 56.1% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply -11.9% downside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $117.70M↑ | $108.39M↑ | $100.06M↑ | $86.68M↑ | $84.69M |
| Gross Profit | $84.07M↑ | $72.87M↑ | $69.40M↑ | $58.02M↑ | $56.27M |
| Operating Income | $1.80M↑ | -$6.04M↓ | -$246,000↑ | -$10.77M↓ | -$8.01M |
| Net Income | $2.81M↑ | -$4.11M↓ | $1.68M↑ | -$8.57M↑ | -$10.35M |
Peer Comparison
JNJUNHPFE
Fundamentals
CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney tra...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.27B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-2.61%
Volume
Today's trading volume
479,089
Recent News
CareDx's CEO Sells 17K Shares
CareDx, a leader in transplant diagnostics, saw a key insider reduce his direct holdings amid a series of scheduled transactions.
CareDx (CDNA) Moves 11.5% Higher: Will This Strength Last?
CareDx (CDNA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
CareDx (CDNA) Valuation Check After Choppy Trading And Growing AI Diagnostics Story
CareDx at a glance CareDx (CDNA) has drawn investor attention after a period of mixed recent returns, with the stock roughly flat over the past month but higher over the past 3 months and the past year. See our latest analysis for CareDx. Recent trading has been choppy, with the share price down 3.7% over the past week but ahead over the past quarter and year to date. This suggests momentum has been improving after earlier weakness. If you are looking beyond CareDx and want to see what else...
CareDx Sharpens Precision Diagnostics Push With Naveris Deal, AlloHeme Plans
CareDx (NASDAQ:CDNA) executives outlined the company’s strategy to focus on precision diagnostics, expand into minimal residual disease testing and improve profitability during a Goldman Sachs-hosted discussion. Chief Executive Officer John Hanna said CareDx has reshaped its portfolio around areas
CareDx Highlights 39% Q1 Growth, Naveris Oncology Push at Jefferies
CareDx (NASDAQ:CDNA) executives outlined the company’s growth strategy, first-quarter performance and pipeline priorities during a presentation at the Jefferies Healthcare Conference, emphasizing transplant diagnostics, specialty oncology and digital workflow integration. John Hanna, chief executiv